Compare QURE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QURE | ABCL |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | Netherlands | Canada |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2013 | 2020 |
| Metric | QURE | ABCL |
|---|---|---|
| Price | $27.85 | $6.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | ★ $45.00 | $8.40 |
| AVG Volume (30 Days) | 1.9M | ★ 8.3M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.67 | 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | $13,107,000.00 | ★ $75,128,000.00 |
| Revenue This Year | $126.12 | N/A |
| Revenue Next Year | $200.43 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $8.73 | $2.09 |
| 52 Week High | $71.50 | $6.52 |
| Indicator | QURE | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 68.49 | 74.81 |
| Support Level | $20.20 | $3.32 |
| Resistance Level | $29.03 | $6.52 |
| Average True Range (ATR) | 1.74 | 0.46 |
| MACD | -0.17 | 0.12 |
| Stochastic Oscillator | 75.56 | 97.17 |
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.